Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas Junshi will continue to be responsible for the promotion of other indications in core areas The companies will continue to explore business collaborations in overseas markets including emerging markets
SHANGHAI, China, March 01, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Company has entered into an exclusive promotion agreement with AstraZeneca Pharmaceutical Co., Ltd. (“AstraZeneca Pharmaceutical” or the “Promoter”), pursuant to which Junshi Biosciences will grant AstraZeneca Pharmaceutical the exclusive promo